We offer a specialized service based on a unique human whole-blood loop assay, for detection of acute immune-related side effects of biopharmaceuticals (cytokine release), which provides a better understanding of first-in-man reactions prior to clinical trial entry. The assay platform can also be used to perform mode-of-action studies.
We are developing a new generation therapeutic peptide-based immuno-oncology vaccine powered by proprietary and patent-protected advanced TET technology that will enhance both peptide uptake and cellular immune activation. Our strategy is based on the delivery of our vaccine in an antigen-antibody immune complex formula.
Are you interested in using our whole-blood loop model to assess toxicity or/and efficacy of your drug candidate? Contact us to find out how we can help you!
Are you interested in our patented TET-technology? Or would you like to recieve more information about investment opportunities? Sign up for our latest news!
Meet us at Nordic Life Science Days in Stockholm Waterfront, September 10-12. During the conference Justyna Leja-Jarblad, COO will be available for partnering meetings. If you are interested in our Immuno-Service, potential collaboration or insights regarding preclinical drug development, contact us through partneringONE.
We are proud to announce that Immuneed is one of the winners of the Bona Postulata prize 2018, alongside our collaborators, Clinical Trial Consultants (CTC).